Losortan Potassium Tablet, Film Coated
Product Images NDC 50268-504

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 50268-504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg (504 15 25mg)

Losartan Potassium is a prescription drug that is available in the form of tablets. The package contains 50 tablets in a unit dose of 5 X 10. Each tablet contains 25mg of Losartan Potassium USP. The usual dosage details are available in the package insert. The tablets should be stored at 20-25°C (68° to 77°F) in a controlled room temperature condition, protected from light. It is important to keep all medications, including Losartan Potassium, out of the reach of children. This medication is manufactured by Avkare and it is Rx-only.*

FDA Label Image

50mg (505 15 50mg)

Losartan Potassium Tablets USP is a prescription-only medication that contains 50 mg of losartan potassium. The package contains 50 tablets (5 x 10 unit dose) and should be stored at a controlled room temperature protected from light. The manufacturer is AVKARE, located in Pulaski, TH 38475. Patients should consult with their physician for complete prescribing information.*

FDA Label Image

100mg (506 15 100mg)

This is a description of a medication called Losartan Potassium in tablet form with a dosage of 100mg per tablet. The medication is only available through a prescription, and each pack comes with 50 tablets. The box contains the National Drug Code (NDC) number which is 50268-506-15. The medication is stored between 20 to 25 degrees Celsius and must be protected from light. The usual dosage is advised through a package insert, and it is recommended to keep the medication out of reach of children. The text also includes a reference to a company named Avkare.*

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

This appears to be a chart or graph related to a study comparing the effectiveness of two drugs, Atenolol and Losartan Potassium. The chart mentions a percentage related to the primary endpoint of the study and an adjusted risk reduction of 13%, with a p-value of 0.021. There are also time intervals represented on the chart, ranging from 18 to 66 months, suggesting that the study was conducted over a period of several years.*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

This is a table showing the percentage of patients who experienced fatal/non-fatal stroke while taking Atenolol and Losartan Potassium. The table also indicates an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted over a period of 66 months.*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

Not available. The given text appears to be a few errors and random characters and doesn't convey any coherent information.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

The text appears to be a table showing the percentage of patients with an event, risk reduction, and p-value for Losartan Potassium Tablet and Placebo. However, without additional context, it is difficult to determine the specific details of the study or what the numbers represent.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.